1,383
edits
Changes
Jump to navigation
Jump to search
Line 18:
Line 18: − + + Line 24:
Line 25: − + Line 32:
Line 33: − + Line 46:
Line 47: − + Line 55:
Line 56: − +
no edit summary
*Start recruiting a research team
*Start recruiting a research team
==10/2 Summary==
==Weekly Summaries==
===10/2 Summary===
*E-mailed slides to Nina and followed up on study. It is currently paused due to a hyperbaric PF bupivacaine shortage at OHSU.
*E-mailed slides to Nina and followed up on study. It is currently paused due to a hyperbaric PF bupivacaine shortage at OHSU.
*Texted Brandon about which journals to submit to. 1st choice: A&A, 2nd choice: Journal for Obstetric Anesthesia
*Texted Brandon about which journals to submit to. 1st choice: A&A, 2nd choice: Journal for Obstetric Anesthesia
*Hamilton and I talked about why ketamine causes lasting changes in the brain long after the drug is gone. Is it a change to a gap junction network? '''Is it anti-inflammatory circulating EVs?'''. There are three papers on MedLine related to ketamine and EVs, none of which look at (anti-)inflammatory molecules. '''Do circulating EVs after propofol anesthetic also contain the inflammatory cytokines that are seen after isoflurane?'''
*Hamilton and I talked about why ketamine causes lasting changes in the brain long after the drug is gone. Is it a change to a gap junction network? '''Is it anti-inflammatory circulating EVs?'''. There are three papers on MedLine related to ketamine and EVs, none of which look at (anti-)inflammatory molecules. '''Do circulating EVs after propofol anesthetic also contain the inflammatory cytokines that are seen after isoflurane?'''
==10/6 Summary==
===10/6 Summary===
*Pitched multi-centre trial to Brandon. E-mailed slides in .ppt format to Nina.
*Pitched multi-centre trial to Brandon. E-mailed slides in .ppt format to Nina.
*Met w/ Norm about depression research (Brian Mickey and Grace Lee) and promotion requirements (Harriet Hopf). '''Need to read this paper about ketamine having an active metabolite that sticks around, explaining its sustained antidepressant effects''' ([https://scholar.googleusercontent.com/scholar.bib?q=info:oxmvfF2RMfcJ:scholar.google.com/&output=citation&scisdr=CiBKb9IEEIjgixuUERc:ACTRDVEAAAAAas-SCRfDvqsYSFStZqKmI5mpZP0&scisig=ACTRDVEAAAAAas-SCWl_hrwNxs7LrCdW_sSZWZk&scisf=4&ct=citation&cd=-1&hl=en Nature paper]).
*Met w/ Norm about depression research (Brian Mickey and Grace Lee) and promotion requirements (Harriet Hopf). '''Need to read this paper about ketamine having an active metabolite that sticks around, explaining its sustained antidepressant effects''' ([https://scholar.googleusercontent.com/scholar.bib?q=info:oxmvfF2RMfcJ:scholar.google.com/&output=citation&scisdr=CiBKb9IEEIjgixuUERc:ACTRDVEAAAAAas-SCRfDvqsYSFStZqKmI5mpZP0&scisig=ACTRDVEAAAAAas-SCWl_hrwNxs7LrCdW_sSZWZk&scisf=4&ct=citation&cd=-1&hl=en Nature paper]).
*[https://pmc.ncbi.nlm.nih.gov/articles/PMC12998346/ Remimazolam targets]: the theoretical initial target concentration of remimazolam may be 0.1 µg/mL for light sedation, 0.2 µg/mL for moderate sedation, and 0.3 µg/mL for deep sedation in elderly patients (70 years), and 1.5 or 2 times those concentrations in middle-aged (45 years) or young adult (20 years) patients. Dose adjust upwards by 10% in females, down by 20% in obesity or ASA III/IV.
*[https://pmc.ncbi.nlm.nih.gov/articles/PMC12998346/ Remimazolam targets]: the theoretical initial target concentration of remimazolam may be 0.1 µg/mL for light sedation, 0.2 µg/mL for moderate sedation, and 0.3 µg/mL for deep sedation in elderly patients (70 years), and 1.5 or 2 times those concentrations in middle-aged (45 years) or young adult (20 years) patients. Dose adjust upwards by 10% in females, down by 20% in obesity or ASA III/IV.
==10/14 Summary==
===10/14 Summary===
*Attended SandLab meeting.
*Attended SandLab meeting.
*Called Christian (consistently has Wed/Thu off, added me to two IRB protocols after I uploaded CITI competency to ERICA system)
*Called Christian (consistently has Wed/Thu off, added me to two IRB protocols after I uploaded CITI competency to ERICA system)
*IARS abstract submission deadline is 12/6 (methohexital, ketamine depression, SCD-PV)
*IARS abstract submission deadline is 12/6 (methohexital, ketamine depression, SCD-PV)
==10/20 Summary==
===10/20 Summary===
*Reached out to Houman re: Methohexital data. Lit review of methoxital going back to 1992.
*Reached out to Houman re: Methohexital data. Lit review of methoxital going back to 1992.
*Figured out software and access: web disk (use ethernet, VPN, or eduroam), GitHub repos, EEGLAB, MatLab, Anaconda
*Figured out software and access: web disk (use ethernet, VPN, or eduroam), GitHub repos, EEGLAB, MatLab, Anaconda
*Submitted NIH Bio Sketch and project summary for possible matching with MSARF student next summer.
*Submitted NIH Bio Sketch and project summary for possible matching with MSARF student next summer.
==10/29 Plan==
===10/29 Summary===
*Requested key for desk and put my name up
*Requested key for desk and put my name up
*Touched base with Grace about retrospective ketamine study
*Touched base with Grace about retrospective ketamine study